

# Michael Roth

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12187430/publications.pdf>

Version: 2024-02-01

29  
papers

1,042  
citations

623734

14  
h-index

477307

29  
g-index

29  
all docs

29  
docs citations

29  
times ranked

2065  
citing authors

#	ARTICLE	IF	CITATIONS
1	Barriers to Pediatric Oncologist Enrollment of Adolescents and Young Adults on a Cross-Network National Clinical Trials Network Supportive Care Cancer Clinical Trial. <i>Journal of Adolescent and Young Adult Oncology</i> , 2022, 11, 117-121.	1.3	8
2	Improved Survival of Young Adults with Cancer Following the Passage of the Affordable Care Act. <i>Oncologist</i> , 2022, 27, 135-143.	3.7	3
3	Shared barriers and facilitators to enrollment of adolescents and young adults on cancer clinical trials. <i>Scientific Reports</i> , 2022, 12, 3875.	3.3	11
4	Provider and staff crisis well-being associated with trust in leadership and baseline burnout. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29497.	1.5	2
5	Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Cancers</i> , 2022, 14, 150.	3.7	30
6	Venetoclax and Decitabine in Pediatric Refractory T-cell Lymphoblastic Lymphoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, 43, e991-e996.	0.6	9
7	Prognostic and Therapeutic Utility of Variably Expressed Cell Surface Receptors in Osteosarcoma. <i>Sarcoma</i> , 2021, 2021, 1-10.	1.3	6
8	Impact of Lagtime, Health Insurance Type, and Income Status at Diagnosis on the Long-Term Survival of Adolescent and Young Adult Cancer Patients. <i>Journal of Adolescent and Young Adult Oncology</i> , 2021, 10, 164-174.	1.3	8
9	Patterns of National Cancer Institute-sponsored Clinical Trial Enrollment in Black Adolescents and Young Adults. <i>Cancer Medicine</i> , 2021, 10, 7620-7628.	2.8	9
10	Systematic review of barriers and facilitators to clinical trial enrollment among adolescents and young adults with cancer: Identifying opportunities for intervention. <i>Cancer</i> , 2020, 126, 949-957.	4.1	44
11	The Children's Oncology Group Adolescent and Young Adult Responsible Investigator Network: A New Model for Addressing Site-Level Factors Impacting Clinical Trial Enrollment. <i>Journal of Adolescent and Young Adult Oncology</i> , 2020, 9, 522-527.	1.3	13
12	Pediatric Hematologists Report Infrequent Prognosis Discussions in the Routine Care of Children with Sickle Cell Disease. <i>Journal of Health Care for the Poor and Underserved</i> , 2020, 31, 398-423.	0.8	4
13	Development of acute lymphoblastic leukemia following treatment for acute myeloid leukemia in children with Down syndrome: A case report and retrospective review of Children's Oncology Group acute myeloid leukemia trials. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27700.	1.5	6
14	Down-regulation of Skp2 expression inhibits invasion and lung metastasis in osteosarcoma. <i>Scientific Reports</i> , 2018, 8, 14294.	3.3	45
15	Genetically transforming human osteoblasts to sarcoma: development of an osteosarcoma model. <i>Genes and Cancer</i> , 2017, 8, 484-494.	1.9	26
16	CD49b inhibits osteogenic differentiation and plays an important role in osteosarcoma progression. <i>Oncotarget</i> , 2017, 8, 87848-87859.	1.8	6
17	Targeted therapy of osteosarcoma with radiolabeled monoclonal antibody to an insulin-like growth factor-2 receptor (IGF2R). <i>Nuclear Medicine and Biology</i> , 2016, 43, 812-817.	0.6	28
18	Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glebatumumab Vedotin, for the Treatment of Osteosarcoma. <i>Pediatric Blood and Cancer</i> , 2016, 63, 32-38.	1.5	46

#	ARTICLE	IF	CITATIONS
19	Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma. <i>Clinical Sarcoma Research</i> , 2015, 5, 4.	2.3	55
20	Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia. <i>Nature Medicine</i> , 2015, 21, 1172-1181.	30.7	112
21	Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone. <i>Leukemia and Lymphoma</i> , 2014, 55, 2901-2906.	1.3	11
22	Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma. <i>Cancer</i> , 2014, 120, 548-554.	4.1	130
23	Satb1 regulates the self-renewal of hematopoietic stem cells by promoting quiescence and repressing differentiation commitment. <i>Nature Immunology</i> , 2013, 14, 437-445.	14.5	92
24	Attitudes and Practices of Pediatric Oncologists Regarding Methadone Use in the Treatment of Cancer-related Pain. <i>Journal of Pediatric Hematology/Oncology</i> , 2013, 35, 103-107.	0.6	12
25	Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 1667-1675.	3.3	10
26	Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. <i>Blood</i> , 2012, 120, 386-394.	1.4	146
27	Stem Cell Transplant for Children with Sickle Cell Anemia: Parent and Patient Interest. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1709-1715.	2.0	32
28	Career burnout among pediatric oncologists. <i>Pediatric Blood and Cancer</i> , 2011, 57, 1168-1173.	1.5	80
29	An assessment of the current state of palliative care education in pediatric hematology/oncology fellowship training. <i>Pediatric Blood and Cancer</i> , 2009, 53, 647-651.	1.5	58